SRx Health Solutions Inc. (SRXH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SRx Health Solutions Inc. (SRXH) stock price & volume — 10-year historical chart
SRx Health Solutions Inc. (SRXH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
SRx Health Solutions Inc. (SRXH) competitors in Generics and biosimilars manufacturers — business model, growth, and fundamentals comparison
SRx Health Solutions Inc. (SRXH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SRx Health Solutions Inc. (SRXH) annual income statement — 10-year revenue, gross profit & net income history
| Line item | Sep'22 | Sep'23 | TTM |
|---|---|---|---|
| Sales/Revenue | 92.63M | 118.94M | 18.61M |
| Revenue Growth % | - | 28.4% | - |
| Cost of Goods Sold | 79.33M | 95.33M | 11.35M |
| COGS % of Revenue | 85.64% | 80.15% | - |
| Gross Profit | 13.31M▲ 0% | 23.61M▲ 77.5% | 5.08M▲ 0% |
| Gross Margin % | 14.36% | 19.85% | - |
| Gross Profit Growth % | - | 77.45% | - |
| Operating Expenses | 14.47M | 29.42M | 23.25M |
| OpEx % of Revenue | 15.62% | 24.73% | - |
| Selling, General & Admin | 13.14M | 29.49M | 20.56M |
| SG&A % of Revenue | 14.19% | 24.8% | - |
| Research & Development | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 1.33M | -75.1K | 1000K |
| Operating Income | -1.17M▲ 0% | -5.81M▼ 397.9% | -18.51M▲ 0% |
| Operating Margin % | -1.26% | -4.88% | - |
| Operating Income Growth % | - | -397.9% | - |
| EBITDA | -539.4K | -4.1M | -17.52M |
| EBITDA Margin % | -0.58% | -3.45% | - |
| EBITDA Growth % | - | -660.81% | - |
| D&A (Non-Cash Add-back) | 627.01K | 1.7M | 992.4K |
| EBIT | -1.17M | -8.76M | -15.49M |
| Net Interest Income | -753.71K | -2.05M | -917.32K |
| Interest Income | 0 | 0 | 57.68K |
| Interest Expense | 753.71K | 2.05M | 975K |
| Other Income/Expense | -842.77K | -5.13M | 860K |
| Pretax Income | -2.01M▲ 0% | -10.94M▼ 444.6% | -17.65M▲ 0% |
| Pretax Margin % | -2.17% | -9.2% | -94.86% |
| Income Tax | 440.21K | 196.58K | 1.56M |
| Effective Tax Rate % | -21.91% | -1.8% | -8.82% |
| Net Income | -2.45M▲ 0% | -11.14M▼ 354.7% | -15.8M▲ 0% |
| Net Margin % | -2.64% | -9.36% | - |
| Net Income Growth % | - | -354.72% | - |
| Net Income (Continuing) | -2.45M | -11.14M | -19.21M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -3.48▲ 0% | -0.90▲ 74.1% | -▲ 0% |
| EPS Growth % | - | 74.14% | - |
| EPS (Basic) | -3.48 | -0.90 | - |
| Diluted Shares Outstanding | 704.18K | 12.39M | 20.4M |
| Basic Shares Outstanding | 704.18K | 12.39M | 20.4M |
| Dividend Payout Ratio | - | - | - |
SRx Health Solutions Inc. (SRXH) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'22 | Sep'23 | TTM |
|---|---|---|---|
| Total Current Assets | 14.8M | 25.13M | 24.53M |
| Cash & Short-Term Investments | 1.66M | 2.07M | 912K |
| Cash Only | 1.66M | 2.07M | 912K |
| Short-Term Investments | 0 | 0 | 0 |
| Accounts Receivable | 3.38M | 7.06M | 8.15M |
| Days Sales Outstanding | 13.32 | 21.66 | 112.42 |
| Inventory | 4.02M | 5.72M | 5.13M |
| Days Inventory Outstanding | 18.48 | 21.9 | 132.97 |
| Other Current Assets | 5.31M | 9.56M | 0 |
| Total Non-Current Assets | 19.99M | 39.38M | 9.46M |
| Property, Plant & Equipment | 7.36M | 10.64M | 7.79M |
| Fixed Asset Turnover | 12.59x | 11.18x | 4.71x |
| Goodwill | 8.78M | 18.48M | 0 |
| Intangible Assets | 3.78M | 9.79M | 1.12M |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 61.54K | 473.41K | 676.27K |
| Total Assets | 34.79M▲ 0% | 64.51M▲ 85.5% | 33.98M▲ 0% |
| Asset Turnover | 2.66x | 1.84x | 0.83x |
| Asset Growth % | - | 85.46% | 0% |
| Total Current Liabilities | 22.04M | 65.5M | 74.11M |
| Accounts Payable | 13.58M | 24.36M | 38.4M |
| Days Payables Outstanding | 62.51 | 93.28 | 667.17 |
| Short-Term Debt | 5.66M | 34.6M | 30.06M |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 1.88M | 5.2M | 1.22M |
| Current Ratio | 0.67x | 0.38x | 0.38x |
| Quick Ratio | 0.49x | 0.30x | 0.30x |
| Cash Conversion Cycle | -30.71 | -49.73 | -421.78 |
| Total Non-Current Liabilities | 11.82M | 5.3M | 5.76M |
| Long-Term Debt | 8.99M | 0 | 1.9M |
| Capital Lease Obligations | 2.3M | 3.57M | 3.86M |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 529.99K | 1.73M | 0 |
| Total Liabilities | 33.86M | 70.8M | 79.86M |
| Total Debt | 17.85M | 39.38M | 37.01M |
| Net Debt | 16.19M | 37.31M | 36.09M |
| Debt / Equity | 19.25x | - | -0.81x |
| Debt / EBITDA | - | - | -2.11x |
| Net Debt / EBITDA | - | - | -2.06x |
| Interest Coverage | -1.55x | -2.83x | -15.89x |
| Total Equity | 927.48K▲ 0% | -6.29M▼ 778.2% | -45.88M▲ 0% |
| Equity Growth % | - | -778.15% | 0% |
| Book Value per Share | 1.32 | -0.51 | -2.25 |
| Total Shareholders' Equity | 927.48K | -6.29M | -45.88M |
| Common Stock | 7.27M | 8.8M | 21K |
| Retained Earnings | -6.34M | -17.58M | -98.42M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 2.49M | 13.88M |
| Minority Interest | 0 | 0 | 0 |
SRx Health Solutions Inc. (SRXH) cash flow — operating, investing & free cash flow history
| Line item | Sep'22 | Sep'23 | TTM |
|---|---|---|---|
| Cash from Operations | 4.67M | 3.87M | 2.85M |
| Operating CF Margin % | 5.04% | 3.25% | - |
| Operating CF Growth % | - | -17.16% | 0% |
| Net Income | -2.45M | -11.14M | -16.1M |
| Depreciation & Amortization | 1.33M | 2.87M | 26K |
| Stock-Based Compensation | 0 | 2.95M | 280K |
| Deferred Taxes | 0 | 0 | 2K |
| Other Non-Cash Items | 7.31M | 15.35M | 15.18M |
| Working Capital Changes | -1.53M | -6.16M | 997K |
| Change in Receivables | 565.47K | -4.96M | 558K |
| Change in Inventory | -1.89M | -746.55K | -643K |
| Change in Payables | 0 | 0 | 1.3M |
| Cash from Investing | -6.83M | -19.78M | -1.13M |
| Capital Expenditures | -244.72K | -1.27M | -7K |
| CapEx % of Revenue | 0.26% | 1.07% | - |
| Acquisitions | -5.67M | -13.23M | 0 |
| Investments | - | - | - |
| Other Investing | -914.45K | -5.28M | -1.12M |
| Cash from Financing | 3.8M | 16.43M | -1.19M |
| Debt Issued (Net) | 3.91M | 11.38M | -1.19M |
| Equity Issued (Net) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 |
| Other Financing | -107.88K | 5.06M | 0 |
| Net Change in Cash | 1.66M▲ 0% | 519K▼ 68.7% | -1.93M▲ 0% |
| Free Cash Flow | 3.13M▲ 0% | 1.58M▼ 49.7% | 377K▲ 0% |
| FCF Margin % | 3.38% | 1.32% | - |
| FCF Growth % | - | -49.73% | - |
| FCF per Share | 4.45 | 0.13 | 0.13 |
| FCF Conversion (FCF/Net Income) | -1.91x | -0.35x | -0.02x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 |
SRx Health Solutions Inc. (SRXH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | TTM |
|---|---|---|
| Return on Equity (ROE) | - | 78.34% |
| Return on Invested Capital (ROIC) | -18.09% | -18.09% |
| Gross Margin | 19.85% | 27.28% |
| Net Margin | -9.36% | -84.93% |
| Debt / Equity | - | -0.81x |
| Interest Coverage | -2.83x | -15.89x |
| FCF Conversion | -0.35x | -0.02x |
| Revenue Growth | 28.4% | - |
SRx Health Solutions Inc. (SRXH) stock FAQ — growth, dividends, profitability & financials explained
SRx Health Solutions Inc. (SRXH) reported $118.9M in revenue for fiscal year 2023. This represents a 28% increase from $92.6M in 2022.
SRx Health Solutions Inc. (SRXH) grew revenue by 28.4% over the past year. This is strong growth.
SRx Health Solutions Inc. (SRXH) reported a net loss of $11.1M for fiscal year 2023.
SRx Health Solutions Inc. (SRXH) generated $1.6M in free cash flow for fiscal year 2023. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
SRx Health Solutions Inc. (SRXH) financial analysis — history, returns, DCA and operating performance tools
Historical returns with dividends reinvested
Dollar cost averaging vs lump sum
Yield, growth, payout safety & DRIP
EPS trends, net income & profitability
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of market, efficiency and balance-sheet ratios
DCF intrinsic value, peer multiples & estimates